Anavex Life Sciences Corp (AVXL)

[TTTav66]

Soon to be published mini review article by the team at McGill University who have previously conducted and published pre-clinical work on Anavex 3-71 (AF710B):

https://www.frontiersin.org/articles/10.3389/fphar.2019.00189/full?fbclid=IwAR1K40Lx1AP1bRGrrGlcoiKvELDMmYBqEv79SxWs89XBdlMHVqdhgCi4rE4

Likewise, AF710B treatment, even at advanced stages of the pathology, displayed remarkable beneficial effects. This drug, in experimental conditions, demonstrated possible “disease-modifying” properties as pathology was frankly diminished and cognition improved after a month of “wash-out” period. The Mini-Review ends with a discussion on the predictive value of similar experimental pharmacological interventions in current rodent tg models. It comments on the validity of some of these approaches for early interventions at preclinical stages of AD, interventions which may be envisioned once definitive diagnosis of AD before clinical presentation is made possible.

3-71 is also touched on in this review article by the same team, published on Feb 12, 2019:

https://www.frontiersin.org/articles/10.3389/fnins.2019.00062/full?fbclid=IwAR209W-ITlBoQWixtBe3dseS4fDcw6norzLV6DlWgnlVaAHRBMeaQFA3wkE

In particular, a combined M1 muscarinic-sigma 1 receptor was shown to have a remarkable effect in diminishing amyloid pathology and the associated cognitive impairment in a transgenic rat model of AD-like amyloid pathology, even after a treatment “wash-out” of a month (equivalent to 3 years of human life).